Patent application number | Description | Published |
20090093525 | Cyclopropyl aryl amide derivatives and uses thereof - Compounds of the formula: | 04-09-2009 |
20090209481 | Nucleoside prodrugs and uses thereof - Compounds having the formula I or II wherein R | 08-20-2009 |
20090215750 | Pyrrolopyrazine kinase inhibitors - The present invention relates to the use of novel pyrrolopyrazine derivatives of Formula I, | 08-27-2009 |
20090215785 | Pyrrolopyrazine kinase inhibitors - The present invention relates to the use of novel pyrrolopyrazine derivatives of Formula I, | 08-27-2009 |
20100267666 | Pyrrolopyrazine kinase inhibitors - The present invention relates to the use of novel pyrrolopyrazine derivatives of Formula I, | 10-21-2010 |
20110015148 | ANTIVIRAL NUCLEOSIDES - 4-Amino-1-((2R,3S,4S,5R)-5-azido-4-hydroxy-5-hydroxymethyl-3-methyl-tetrahydro-furan-2-yl)-1H-pyrimidin-2-one (22) and prodrugs thereof are hepatitis C (HCV) polymerase inhibitors. Also disclosed are compositions and methods for inhibiting HCV and treating HCV-mediated diseases, processes for making the compounds and synthetic intermediates employed in the process. | 01-20-2011 |
20110070190 | HETEROCYCLIC ANTIVIRAL COMPOUNDS - The invention discloses 1-N-substituted-6-(hetero)aryl-1H-thieno[3,2-d]pyrimidin-4-one derivatives of formula | 03-24-2011 |
20110150829 | ANTIVIRAL NUCLEOSIDES - Compounds having the formula I wherein R | 06-23-2011 |
20110172410 | ANTIVIRAL NUCLEOSIDES - 4-Amino-1-((2R,3S,4S,5R)-5-azido-4-hydroxy-5-hydroxymethyl-3-methyl-tetrahydro-furan-2-yl)-1H-pyrimidin-2-one (22) and prodrugs thereof are hepatitis C(HCV) polymerase inhibitors. Also disclosed are compositions and methods for inhibiting HCV and treating HCV-mediated diseases, processes for making the compounds and synthetic intermediates employed in the process. | 07-14-2011 |
20120039845 | NUCLEOSIDE PRODRUGS AND USES THEREOF - Compounds having the formula I or II, wherein R | 02-16-2012 |
20120070411 | SUBSTITUTED NUCLEOTIDE ANALOGS - Disclosed herein are phosphoroamidate nucleotide analogs, methods of synthesizing phosphoroamidate nucleotide analogs and methods of treating diseases and/or conditions such as viral infections, cancer, and/or parasitic diseases with the phosphoroamidate nucleotide analogs. | 03-22-2012 |
20120070415 | AZIDO NUCLEOSIDES AND NUCLEOTIDE ANALOGS - Disclosed herein are nucleosides, nucleotides and analogs thereof, pharmaceutical compositions that include one or more of nucleosides, nucleotides and analogs thereof, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a disease and/or a condition, including an infection from a paramyxovirus and/or an orthomyxovirus, with a nucleoside, a nucleotide and an analog thereof. Examples of viral infections include a respiratory syncytial viral (RSV) and influenza infection. | 03-22-2012 |
20120071434 | SUBSTITUTED NUCLEOTIDE ANALOGS - Disclosed herein are phosphorothioate nucleotide analogs, methods of synthesizing phosphorothioate nucleotide analogs and methods of treating diseases and/or conditions such as viral infections, cancer, and/or parasitic diseases with the phosphorothioate nucleotide analogs. | 03-22-2012 |
20120165286 | CYCLIC NUCLEOTIDE ANALOGS - Disclosed herein are cyclic nucleotide analogs, methods of synthesizing cyclic nucleotide analogs and methods of treating diseases and/or conditions such as viral infections, cancer, and/or parasitic diseases with cyclic nucleotide analogs. | 06-28-2012 |
20130165400 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF - Disclosed herein are nucleosides, nucleotides and analogs thereof, pharmaceutical compositions that include one or more of nucleosides, nucleotides and analogs thereof, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a disease and/or a condition, including an infection from a paramyxovirus and/or an orthomyxovirus, with a nucleoside, a nucleotide and an analog thereof. | 06-27-2013 |
20130252920 | PHARMACEUTICAL COMBINATIONS COMPRISING A THIONUCLEOTIDE ANALOG - Disclosed herein are pharmaceutical compositions that can include a thionucleotide analog for use in combination therapy with other agents. Also disclosed herein are methods of treating diseases and/or conditions with a pharmaceutical composition that can include a thionucleotide analog in combination therapy with other agents. | 09-26-2013 |
20140179627 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF - Disclosed herein are nucleotide analogs, methods of synthesizing nucleotide analogs and methods of treating diseases and/or conditions such as a HCV infection with one or more nucleotide analogs. | 06-26-2014 |
20140179910 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF - Disclosed herein are nucleotide analogs, methods of synthesizing nucleotide analogs and methods of treating diseases and/or conditions such as a HCV infection with one or more nucleotide analogs. | 06-26-2014 |
20140303108 | CYCLIC NUCLEOTIDE ANALOGS - Disclosed herein are cyclic nucleotide analogs, methods of synthesizing cyclic nucleotide analogs and methods of treating diseases and/or conditions such as viral infections, cancer, and/or parasitic diseases with cyclic nucleotide analogs. | 10-09-2014 |
20150038451 | SUBSTITUTED NUCLEOTIDE ANALOGS - Disclosed herein are phosphorothioate nucleotide analogs, methods of synthesizing phosphorothioate nucleotide analogs and methods of treating diseases and/or conditions such as viral infections, cancer, and/or parasitic diseases with the phosphorothioate nucleotide analogs. | 02-05-2015 |
20150051167 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF - Disclosed herein are nucleosides, nucleotides and analogs thereof, pharmaceutical compositions that include one or more of nucleosides, nucleotides and analogs thereof, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a disease and/or a condition, including an infection from a paramyxovirus and/or an orthomyxovirus, with a nucleoside, a nucleotide and an analog thereof. | 02-19-2015 |
20150072982 | AZA-PYRIDONE COMPOUNDS AND USES THEREOF - Disclosed herein are aza-pyridone compounds, pharmaceutical compositions that include one or more aza-pyridone compounds, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a disease and/or a condition, including an orthomyxovirus infection, with an aza-pyridone compounds. Examples of an orthomyxovirus viral infection include an influenza infection. | 03-12-2015 |
20150105341 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF - Disclosed herein are nucleosides, nucleotides and nucleotide analogs, methods of synthesizing the same and methods of treating diseases and/or conditions such as a Picornavirus and/or Flaviviridae infection with one or more nucleosides, nucleotides and nucleotide analogs. | 04-16-2015 |
20150183819 | AZIDO NUCLEOSIDES AND NUCLEOTIDE ANALOGS - Disclosed herein are nucleosides, nucleotides and analogs thereof, pharmaceutical compositions that include one or more of nucleosides, nucleotides and analogs thereof, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a disease and/or a condition, including an infection from a paramyxovirus and/or an orthomyxovirus, with a nucleoside, a nucleotide and an analog thereof. Examples of viral infections include a respiratory syncytial viral (RSV) and influenza infection. | 07-02-2015 |
Patent application number | Description | Published |
20130030588 | Multiphase Electrical Power Construction and Assignment at Minimal Loss - In a multiphase electrical power construction and assignment, a processor: determines a phase and voltage configuration for bi-directional power device pairs; determines a given bi-directional power device pair is to be coupled to a given phase connection based on the configuration; determines whether the given bi-directional power devices in the given bi-directional power device pair are to be coupled to each other; confirms that the given bi-directional power device pair is not coupled to any of the plurality of phase connections; couples the given bi-directional power device pair to the given phase connections, where power signals of the given bi-directional power device pair are synchronized with a power signal of the given phase connection; and in response to determining that the given bi-directional power devices are to be coupled to each other, couples each of the bi-directional power devices to a short bus. | 01-31-2013 |
20130141142 | Multiphase Electrical Power Assignment at Minimal Loss - In a multiphase electrical power assignment, a processor: receives instructions to connect a bi-directional power device to a multiphase premise power source; determines that the power device is to be coupled to a target phase's phase connection; confirms that the power device is not coupled to any phase connections; and couples the power device to the phase connection, where the power device's power signal is synchronized with the phase connection's power signal. When the power device is in a connected state, the processor: issues a command to place each phase connection switch in an open state; in response to confirming that the phase connection switches are in the open state, issues commands to the power device so that a power signal of the power device will be synchronized with the target phase; and closes the phase connection switch corresponding to the target phase. | 06-06-2013 |
20140324241 | MULTIPHASE ELECTRICAL POWER CONSTRUCTION AND ASSIGNMENT AT MINIMAL LOSS - In a multiphase electrical power construction and assignment, a processor: determines a phase and voltage configuration for bi-directional power device pairs; determines a given bi-directional power device pair is to be coupled to a given phase connection based on the configuration; determines whether the given bi-directional power devices in the given bi-directional power device pair are to be coupled to each other; confirms that the given bi-directional power device pair is not coupled to any of the plurality of phase connections; couples the given bi-directional power device pair to the given phase connections, where power signals of the given bi-directional power device pair are synchronized with a power signal of the given phase connection; and in response to determining that the given bi-directional power devices are to be coupled to each other, couples each of the bi-directional power devices to a short bus. | 10-30-2014 |
20150123601 | BIDIRECTIONAL ENERGY CONVERTER WITH CONTROLLABLE FILTER STAGE - The invention provides a bidirectional converter that operates under an AC generation mode or a charge mode. The bidirectional converter may be a single component or circuit, which may include a DC-DC conversion stage using a unique “Smith 2 Stage conversion” technique and a DC-AC conversion stage or AC-DC conversion stage using a switchable filter depending on the mode. During the charge mode, the converter may be able to control the voltage and current of the DC output using a software algorithm, to match the battery being charged, or the DC receiver. This may enable the converter to control the nature of the DC output so it can be adapted to any energy storage technology. The controllable output voltage and synchronizable frequency may allow the converter to be used in series combinations to achieve a variety of high voltage outputs from simpler building blocks. | 05-07-2015 |